Time-dependent endpoints as predictors of overall survival in multiple myeloma - Wikidata - awgldk - TriplyDB

Time-dependent endpoints as predictors of overall survival in multiple myeloma

Time-dependent endpoints as predictors of overall survival in multiple myeloma

http://www.wikidata.org/entity/Q30538040

about

How we manage autologous stem cell transplantation for patients with multiple myeloma Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.Long-term survival in multiple myeloma.

P2860

Q34019581-FEB2E8C7-5938-4D1E-A018-3A9B54DA4DDC Q38630472-01782C30-6912-4E2A-9A72-30629687E671 Q40186469-069BB34A-9D91-4F10-852D-32C0451B3CA1 Q43008248-DE91B160-AA4E-44DE-9ED8-B351FB338B86

P2860

Time-dependent endpoints as predictors of overall survival in multiple myeloma

http://www.wikidata.org/entity/Q30538040

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@ast

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@en

type

label

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@ast

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@en

prefLabel

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@ast

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@en

P1433

Q30538040-95CD1947-ED45-4FA8-9249-02F57C9C67C5

P1476

Q30538040-50F28BB4-6108-4946-AF7D-AF3A3E199300

P2093

Q30538040-02E1ADEA-4538-43E9-9CE8-CC6E7E1DDCDF

Q30538040-5BD47B5B-9C14-4D62-A012-BE7DA76F4056

Q30538040-5E98AFD4-B4EF-4DAC-9BA5-78DDA1E82123

Q30538040-64DBA9A0-5E3D-451F-8B5E-56B6A16608C9

Q30538040-89A167F9-4DD3-4F87-8A58-048765BC1A91

Q30538040-B7F7097A-05B4-4A22-86C4-E8B60F2CE003

Q30538040-F19AD1DD-2AB8-4BAF-A607-903B2D72D2E1

P2860

Q30538040-006B5DEC-5E12-4B78-834C-CC0F30B8E013

Q30538040-019FCB83-1FE7-4C7B-8F70-418803D9C006

Q30538040-02D1B1CF-C4C1-456A-889B-035DE55A7158

Q30538040-043DA993-1C65-4242-9A5E-ECFF9B719455

Q30538040-07A5BC06-82FA-4DAF-A0D8-F39D0BE9C650

Q30538040-1B52B393-76CA-4E06-9B7C-239C604586C6

Q30538040-21464806-4A55-49F1-A500-590608C812D9

Q30538040-264D83E3-6C5F-49D0-B438-2C0FD9613844

Q30538040-265748D1-07E6-419C-954D-28E5D35A4349

Q30538040-2AF2751A-FE07-454C-9D94-389AF8321FCA

P2888

Q30538040-972B4F3C-3B36-47DE-9731-DA8C7F7935DC

P304

Q30538040-306C0858-51ED-4CE2-870F-5CF7DE6BCF99

P31

Q30538040-B58AB389-7C01-4F0E-8498-42B127B03670

Q30538040-d17b674c-d325-480c-ac42-3e7c4a2c5ece

P356

Q30538040-4F6692D4-12A0-4582-884A-88327B372B32

P407

Q30538040-B8FC4997-C3C4-4EC1-BD50-4CEF1BE72E3D

P478

Q30538040-11A0A714-5326-4CB3-98D0-101821E1F494

P50

Q30538040-37450412-44D9-4C3D-B2DB-C3C7ED3F585E

P577

Q30538040-7F1D840C-C760-4331-A8A3-2208AA527135

P5875

Q30538040-E2DC3049-2EF2-4204-A6DA-BF8E45C337DD

P6179

Q30538040-58E849AE-6663-478E-87B0-F81DD0728468

P698

Q30538040-0A76F0E7-742A-42A8-AA5B-072E18105ACB

P932

Q30538040-B9EA22BA-F75E-4EDB-BD57-D3788C8306BC

P356

1471-2407-13-122

P1433

P1476

Time-dependent endpoints as predictors of overall survival in multiple myeloma

@en

P2093

António B S Parreira

http://www.w3.org/2001/XMLSchema#string

Diana Ferreira

http://www.w3.org/2001/XMLSchema#string

Frederico J Calado

http://www.w3.org/2001/XMLSchema#string

Jorge Félix

http://www.w3.org/2001/XMLSchema#string

João F R Rijo

http://www.w3.org/2001/XMLSchema#string

João M Almeida

http://www.w3.org/2001/XMLSchema#string

Ricardo Rodrigues

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Errors in Variables

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

P2888

1471-2407-13-122

P304

122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-122

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236051799

http://www.w3.org/2001/XMLSchema#string

P6179

1052823714

http://www.w3.org/2001/XMLSchema#string

P698

23497363

http://www.w3.org/2001/XMLSchema#string

P932

3607860

http://www.w3.org/2001/XMLSchema#string